Fetal Bovine Serum Global Market Report 2021 - ResearchAndMarkets.com
DUBLIN--(BUSINESS WIRE)--The "Fetal Bovine Serum Global Market Report 2021: COVID-19 Growth and Change" report has been added to ResearchAndMarkets.com's offering.
The global fetal bovine serum market is expected to grow from $855.80 million in 2020 to $946.25 million in 2021 at a compound annual growth rate (CAGR) of 10.6%. The growth in mainly due to increase in R&D towards development of novel biopharmaceuticals. The market is expected to reach $1,175.36 million in 2025 at a CAGR of 5.6%.
Major players in the fetal bovine serum market are Sartorius AG, GE Healthcare, PAN- Biotech, Thermo Fisher Scientific Inc., Biowest, Bio-Techne, Rocky Mountain Biologicals Inc., Merck KGaA, TCS Biosciences Ltd, Bovogen Biologicals Pty Ltd, Tissue Culture Biologicals, Atlanta Biologicals Inc., Atlas Biologicals, Acess Biologicals, Animal Technologies Inc, Nucleus Biologics, Corning Incorporated, J R Scientific Inc., Cytiva, Axil Scientific Pte Ltd, and Moregate Biotech.
The fetal bovine serum market consists of sales of fetal bovine serum by entities (organizations, sole traders, and partnerships) that are engaged in manufacturing fetal bovine serum and related services. Fetal bovine serum refers to the liquid fraction of clotted blood from fetal calves, with reduced cells, fibrin, and clotting factors. It has high concentration of nutritional and macromolecular factors essential for cell growth and is a critical raw material for animal care, biotechnology, drug development, diagnostics, and other fields of research.
The main types of fetal bovine serum are charcoal stripped, chromatographic, dialyzed fetal bovine serum, exosome depleted, stem cell, others. Charcoal stripped fetal bovine serum has activated carbon that helps lower levels of lipophilic compounds such as hormones, growth factors, and steroids and is used to conduct receptor or estrogen related studies.
Dialyzed fetal bovine serum has reduced concentration of low molecular weight components such as nucleotides, amino acids, hormones, salts and various small proteins in serum and is used in cell culture systems requiring a more defined environment of small molecules. Exosome depleted fetal bovine serum isolates exosomes from cultured cells without the complication of bovine exosomes that are present in conventional FBS and is used for research on exosomes.
The fetal bovine serum is used in drug discovery, cell culture media, in vitro fertilization, human and animal vaccine production, diagnostics, others. Fetal bovine serum is used in various sectors including research and academic institutes, biotechnology and pharmaceutical industry, others.
North America was the largest region in the fetal bovine serum market in 2020. Asia Pacific recorded the fastest growth during the forecast period. The regions covered in this report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.
Increasing collaborations between companies and research intuitions is a key trend gaining popularity in the fetal bovine serum market. Major companies are collaborating for increasing production capabilities, expanding market share and developing new products. For instance, in 2017, US based GE Healthcare collaborated with New Zealand based Oritain for developing an independent test that can confirm the country of origin of fetal bovine serum (FBS) which would help biomanufacturing entities as FBS used in different countries pose different risk levels for virus contamination.
The increasing demand for biopharmaceuticals is expected to drive the growth of the fetal bovine serum market in the forecast period. A biopharmaceutical is a medicinal product that is derived from biological sources such as animals, humans, and microorganisms using biotechnology.
Fetal bovine serum (FBS) is the most widely used substitute for animal cell culture media. Pharmaceutical firms, diagnostic laboratories, and researchers rely heavily on FBS for much of their cell culture requirements in biologics research. The global biologics market is expected to increase from $253.4 billion in 2020 to $420.5 billion by 2025. Therefore, the rising demand for biopharmaceuticals propels the growth of the fetal bovine serum market.
Key Topics Covered:
1. Executive Summary
2. Fetal Bovine Serum Market Characteristics
3. Fetal Bovine Serum Market Trends and Strategies
4. Impact Of COVID-19 On Fetal Bovine Serum
5. Fetal Bovine Serum Market Size and Growth
5.1. Global Fetal Bovine Serum Historic Market, 2015-2020, Billion
5.1.1. Drivers Of The Market
5.1.2. Restraints On The Market
5.2. Global Fetal Bovine Serum Forecast Market, 2020-2025F, 2030F, Billion
5.2.1. Drivers Of The Market
5.2.2. Restraints On the Market
6. Fetal Bovine Serum Market Segmentation
6.1. Global Fetal Bovine Serum Market, Segmentation By Product, Historic and Forecast, 2015-2020, 2020-2025F, 2030F, Billion
- Charcoal Stripped
- Dialyzed Fetal Bovine Serum
- Exosome Depleted
- Stem Cell
6.2. Global Fetal Bovine Serum Market, Segmentation By Application, Historic and Forecast, 2015-2020, 2020-2025F, 2030F, Billion
- Drug Discovery
- Cell Culture Media
- In Vitro Fertilization
- Human and Animal Vaccine Production
6.3. Global Fetal Bovine Serum Market, Segmentation By End-User, Historic and Forecast, 2015-2020, 2020-2025F, 2030F, Billion
- Research and Academic Institutes
- Biotechnology and Pharmaceutical Industry
7. Fetal Bovine Serum Market Regional and Country Analysis
7.1. Global Fetal Bovine Serum Market, Split By Region, Historic and Forecast, 2015-2020, 2020-2025F, 2030F, Billion
7.2. Global Fetal Bovine Serum Market, Split By Country, Historic and Forecast, 2015-2020, 2020-2025F, 2030F, Billion
- Sartorius AG
- GE Healthcare
- PAN- Biotech
- Thermo Fisher Scientific Inc.
- Rocky Mountain Biologicals Inc.
- Merck KGaA
- TCS Biosciences Ltd
- Bovogen Biologicals Pty Ltd
- Tissue Culture Biologicals
- Atlanta Biologicals Inc.
- Atlas Biologicals
- Acess Biologicals
- Animal Technologies Inc
- Nucleus Biologics
- Corning Incorporated
- J R Scientific Inc.
- Axil Scientific Pte Ltd
- Moregate Biotech
For more information about this report visit https://www.researchandmarkets.com/r/efh8mx
Laura Wood, Senior Press Manager
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900